Sjoerd Rodenhuis
Affiliations: | Netherlands Cancer Institute |
Area:
Medical OncologyWebsite:
https://www.myctmm.nl/pro1/general/start.asp?i=2&j=3&k=0&p=0&itemid=116&folder=Cancer&title=Breast%20CareGoogle:
"Sjoerd Rodenhuis"Bio:
http://alba.ub.rug.nl/promotorum/?page=showPerson&promovendus_id=2946
Prof. dr. S. Rodenhuis at the Album Academicum of the University of Amsterdam
Mean distance: 13.7 | S | N | B | C | P |
Parents
Sign in to add mentor| Enno Mandema | grad student | 1983 | RUG (Neurotree) | |
| (Early clinical studies of (NPAz2)2NSOAz: 'SOAz') | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| van Ramshorst MS, Teixeira SC, Koolen BB, et al. (2017) Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 17: 15 |
| Schmitz AMT, Teixeira SC, Pengel KE, et al. (2017) Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. Plos One. 12: e0176782 |
| van Ramshorst MS, van Werkhoven E, Mandjes IA, et al. (2017) Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. European Journal of Cancer (Oxford, England : 1990). 74: 47-54 |
| Lips E, Hoogstraat M, Mulder L, et al. (2017) Abstract PD1-07: Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer Cancer Research. 77 |
| Rossum Av, Oosterkamp H, Werkhoven Ev, et al. (2017) Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) Cancer Research |
| Steenbruggen T, Ramshorst v, Stouthard J, et al. (2017) Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle Cancer Research. 77 |
| Lips EH, Mooyaart AL, Seijen Mv, et al. (2017) Abstract 1751: Systematic bias in genomic breast cancer classification due to selecting cases with high tumor percentage and good RNA quality Cancer Research. 77: 1751-1751 |
| Teixeira SC, Koolen BB, Elkhuizen PH, et al. (2016) PET/CT with F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 43: 625-635 |
| Loo CE, Rigter LS, Pengel KE, et al. (2016) Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Research : Bcr. 18: 82 |
| Ramshorst v, Werkhoven Ev, Mandjes I, et al. (2016) Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study Cancer Research. 76 |